A single-center retrospective observational study indicated that individuals with allergic rhinitis that is aggravated by rheumatic autoimmune illnesses can benefit from allergen immunotherapy, which is a secure and reliable treatment option. Researchers sought to assess safety and efficacy of allergen immunotherapy in 13 patients with concomitant allergic rhinitis and rheumatic autoimmune disease.

Individuals with rheumatic autoimmune disease who stopped receiving allergen immunotherapy were also incorporated in the investigation of changes in activity during a 2-year period commencing from baseline. In this case series study, the Japan Allergic Rhinitis Standard Quality of Life Questionnaire was utilized to examine the efficacy of allergen immunotherapy.

All the participants got sublingual immunotherapy. However, four patients stopped receiving it because of deleterious adverse effects. Three patients' rheumatic autoimmune disease symptoms worsened during the course of the observation period. However, none of the symptoms was directly attributable to allergen immunotherapy. The majority of allergic immunotherapy's side effects were minor.  Owing to aggravation of rhinitis symptoms, only 1 participant needed medication.

The eye and nasal symptom scores of 9 participants who were allowed to continue allergen immunotherapy substantially dropped from 1.67 (1.5-2.0) at baseline to 0.67 (0-1.17) in the second year of therapy. Hence, allergen immunotherapy is anticipated to become a promising treatment modality for people with allergic rhinitis intricated by rheumatic autoimmune diseases who have failed to attain satisfactory improvement with conventional pharmacotherapy.